WASHINGTON — Timing matters when it comes to combining immunotherapy with chemoradiation in limited-stage small cell lung cancer (SCLC), according to the phase 3 NRG-LU005 trial presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting. Investigators did not find a significant survival benefit among patients who received atezolizumab simultaneously with chemoradiation compared …
